Xeris Biopharma Holdings (XERS) Non-Current Assets (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Non-Current Assets came in at $140.3 million in Q1 2026, down 7.65% YoY from $152.0 million in Q1 2025, and down 2.01% on a QoQ basis from $143.2 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Non-Current Assets (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Non-Current Assets data on file, last reported at $140.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 7.65% year-over-year to $140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $578.8 million (down 7.69% YoY) and the FY2025 annual result came in at $143.2 million, down 7.84% from the prior year.
- Non-Current Assets eased to $140.3 million in Q1 2026, from $143.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $173.0 million in Q2 2023 to a low of $140.3 million in Q1 2026.
- A 5-year average of $156.7 million and a median of $157.4 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 2135.57% — and 2025, when it retreated 7.84%.
- Tracing XERS's Non-Current Assets over 5 years: stood at $157.7 million in 2022, then increased by 5.47% to $166.3 million in 2023, then dropped by 6.58% to $155.4 million in 2024, then slipped by 7.84% to $143.2 million in 2025, then retreated by 2.01% to $140.3 million in 2026.
- The last three Non-Current Assets figures came in at $140.3 million (Q1 2026), $143.2 million (Q4 2025), and $146.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.23 Bn | 43.26 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.50 Bn | 39.84 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 32.56 Bn | 30.88 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.62 Bn | 22.82 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.31 Bn | 19.65 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.54 Bn | 15.15 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.38 Bn | 79.59 Mn | 137.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.15 Mn |
| Mar 31, 2026 | 140.33 Mn |
| Dec 31, 2025 | 143.21 Mn |
| Sep 30, 2025 | 146.17 Mn |
| Jun 30, 2025 | 149.11 Mn |
| Mar 31, 2025 | 151.96 Mn |
| Dec 31, 2024 | 155.40 Mn |
| Sep 30, 2024 | 158.31 Mn |
| Jun 30, 2024 | 161.39 Mn |
| Mar 31, 2024 | 163.34 Mn |
| Dec 31, 2023 | 166.34 Mn |
| Sep 30, 2023 | 169.73 Mn |
| Jun 30, 2023 | 173.04 Mn |
| Mar 31, 2023 | 155.85 Mn |
| Dec 31, 2022 | 157.70 Mn |
| Sep 30, 2022 | 154.10 Mn |
| Jun 30, 2022 | 157.41 Mn |
| Mar 31, 2022 | 160.07 Mn |
| Dec 31, 2021 | 161.77 Mn |
| Sep 30, 2021 | 6.89 Mn |